TOSYMRA delivers the efficacy of an injection in a well-tolerated nasal spray1,2
The most common adverse reactions (≥5% and > placebo) with sumatriptan injection (6 mg) were tingling, dizziness/vertigo, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, flushing, feeling of tightness, and numbness.
6-month safety data demonstrates that TOSYMRA is generally well tolerated2
TOSYMRA, with Intravail® technology, effectively delivers sumatriptan intranasally. It may be an alternative for patients who cannot tolerate oral treatments.
In an open-label, repeat-dose study designed to assess the safety and tolerability of TOSYMRA in 167 adult patients who collectively reported 2211 migraines,2
Low rates of triptan-related AEs were reported
3292 doses of TOSYMRA were administered2,3
- A 2.9% triptan-related TEAE rate was demonstrated (94 events out of 3292 individual doses)3
- 5 patients (3%) discontinued due to adverse events3
TEAE=treatment-emergent adverse event.
*Most common triptan-related TEAEs occurring in ≥1% of patients: dizziness, nausea, chest discomfort, paresthesia, feeling hot, feeling jittery, muscle tightness, and vomiting.
Low rates of dysgeusia in the 6-month open-label safety study2
- 21% of patients (n=35) experienced dysgeusia
- The majority of cases were mild (30/35)2
- No severe cases of dysgeusia were reported2
- The per-dose percentage of dysgeusia was 7% (232 cases out of 3292 individual doses)2,5
- In addition to dysgeusia, other common adverse reactions reported with TOSYMRA over the course of 6 months in the open-label trial were application site reactions (36%) and throat irritation (5%)
Each patient has a distinct migraine experience
Meet Bill: Patient with a Busy Lifestyle
Bill has traditionally suffered from 3 migraines per month. However, due to his high-stress job, the frequency of his migraines has almost doubled. He now experiences between 4 to 6 moderate-to-severe migraines per month. Bill’s migraines are rapid in onset, and the severity of each migraine typically builds within 20 minutes.
Bill has tried both oral and nasal triptans. Bill experienced a slower onset of pain relief than he needed, forcing him to lie down for approximately 2 hours.
Bill lives a busy lifestyle and requires a fast, effective, and tolerable migraine medication that won’t interfere with his schedule.
- A treatment option that fits his busy schedule
- A rapid and effective treatment option for migraine pain
- A treatment option that he tolerates well
References: 1. TOSYMRA [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; 2019. 2. Munjal S, Brand-Schieber E, Allenby K, Spierings ELH, Cady RK, Rapoport AM. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. J Headache Pain. 2017;18(1):313. 3. Halvorsen MB, Zachman MB, Munjal S, Rapoport AM. Triptan-Related Adverse Events in a Multicenter, Open-label, Long-Term, Safety Study of DFN-02 (Tosymra™; an Intranasal Spray of Sumatriptan 10 mg Plus Permeation Enhancer DDM), for the Acute Treatment of Migraine. Presented at: PAINWeek 2019; September 3-7, 2019; Las Vegas, NV. 4. Data on file. Upsher-Smith Laboratories, Maple Grove, MN. 5. Halvorsen MB, Zachman MB, Munjal S, Rapoport AM. Dysgeusia Rates in a Multicenter, Open-label, Long-Term, Safety Study of DFN-02 (Tosymra™; an Intranasal Spray of Sumatriptan 10 mg Plus Permeation Enhancer DDM), for the Acute Treatment of Migraine. Presented at: PAINWeek 2019; September 3-7, 2019; Las Vegas, NV.